Reported Sunday, Johnson & Johnson Says Impella Outcomes Depend On Patient Selection, Timing And Post-Procedural Care, Citing Lower Mortality In Three TCT Analyses Versus CHIP-BCIS3; PROTECT IV Results Expected 2027